Cervical Cancer

Question 1

SYSTEMIC THERAPY FOR CERVICAL CANCER: First-line Therapy

Answer 1

Preferred Regimens
PD-L1–positive tumors:
Pembrolizumab + cisplatin/paclitaxel ± bevacizumab (category 1)
Pembrolizumab + carboplatin/paclitaxel ± bevacizumab (category 1)

Cisplatin/paclitaxel/bevacizumab (category 1)
Carboplatin/paclitaxel/bevacizumab

Other Recommended Regimens:
Cisplatin/paclitaxel (category 1)
Carboplatin/paclitaxel
(category 1 for patients who have received prior
cisplatin therapy)
Topotecan/paclitaxel/bevacizumab
(category 1)

Question 2

SYSTEMIC THERAPY FOR CERVICAL CANCER: Second-line or Subsequent Therapy

Answer 2

Preferred Regimens:
Pembrolizumab for:
TMB-H tumors (tumor agnostic FDA approval) or
PD-L1–positive (PD-L1 (CPS ≥1) FDA app
or
MSI-H/dMMR (off label)

Tisotumab vedotin-tftv15 (Tivdak) FDA acc approval per innovaTV 204 2022

Cemiplimab (Libtayo) approved in EU for cervical CA (not FDA approved) based on EMPOWER trial 2022)